Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, HIF-1α (but not HIF-2α) has also been shown to enhance the self-renewal activity of stem-like U251 and U87 GBM cells and to inhibit the induction of differentiation suggesting that the HIF-α isoform dependency involved in the hypoxia-mediated maintenance of GBM stem-like cells may be cell type specific [50–52].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
RetractedGilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
RetractedPonnala, S., Veeravalli, K. K., Chetty, C., Dinh, D. H., & Rao, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026191 · Cited by 24
RetractedWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Research works printed but not linked: 2
- 10.1128/mcb.12.12.5447-5454.1992 · doi:10.1128/mcb.12.12.5447-5454.1992 · Paper page
- Wallace E . PT2385: HIF-2a antagonist for the treatment of VHL mutant ccRCC. Proceedings of : 12th International VHL Medical Symposium. MA, USA, 7–9 April 2016 .
Cited by
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy
Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701291 · Cited by 140
Yin, J., Ge, X. Q., Shi, Z., Chen, Y., Lu, C., Wei, Y., Zeng, A., Wang, X., Yan, W., Zhang, J., et al. (2020) · Theranostics · doi:10.7150/thno.47057 · Cited by 113
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Sun, X., Lv, X., Yan, Y., Zhao, Y., Ma, R., He, M., & Wei, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110623 · Cited by 99
Metadata
- Authors
- Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- Mayo Clinic (US)
- Brain Tumor Center of Excellence Wake Forest Comprehensive Cancer Center Winston-Salem NC 27157 USA
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2018-08-09
- Volume
- 10
- Issue
- 18
- Pages
- 2227-2236
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- PMC
- PMC6479274
- OpenAlex
- W2886561153
- Cited by
- 40
- References
- 85
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 1 · 2018: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Medicinal Chemistry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA012197)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-2α, glioblastoma, glioma stem cells, tumor hypoxia, PT2385, targeted cancer therapy, drug resistance
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Glioma, Humans, Indans, Sulfones, RNA Interference, RNA, Small Interfering, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas. https://app.cochat.ai/papers/10.4155/fmc-2018-0163
- The paper
- Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018). Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2018-0163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.